• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • Chinese Pharmacopoeia 2020 edition – official English translation issued

Chinese Pharmacopoeia 2020 edition – official English translation issued

Chinese Pharmacopoeia 2020
Wednesday, 26 April 2023 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Chinese Pharmacopoeia 2020 edition – official English translation issued

Chinese Pharmacopoeia 2020 edition was translated into English and officially published by the Chinese Pharmacopoeia Commission (CPC) on March 14, 2023. The Chinese edition was released on July 2, 2020, and implemented from December 30, 2020, onwards. The document provides a detailed overview of the China quality standards and specifications for drugs and pharmaceutical products, making it an essential reference for both manufacturers and users of drugs around the world.

Highlights

The Chinese Pharmacopoeia is typically updated every 5 years. Compared to the 2015 edition, the 2020 edition of the Chinese Pharmacopoeia (CP) consists of 5911 monographs, with 319 new additions, 3177 revisions, 10 rejections, and 6 reductions:

  • Volume I of the CP includes 2711 monographs for traditional Chinese medicine (TCM), with 117 additions and 452 revisions.
  • Volume II includes 2712 monographs for chemical drugs, with 117 additions and 2387 revisions.
  • Volume III includes 153 monographs for biological products, with 20 additions and 126 revisions.
  • Volume IV contains 361 general technical requirements, with 38 general requirements for preparations (35 revisions), 281 general testing methods and other general chapters (35 additions, 51 revisions), and 42 guidelines (12 additions, 12 revisions).
  • The English version of the CP includes 335 monographs for pharmaceutical excipients, with 65 additions and 212 revisions.

One of the main features of the latest edition of the Pharmacopoeia is its focus on modern technologies and novel drug development approaches. This includes updated guidelines on biologics, traditional Chinese medicines and complementary therapies, making it a more comprehensive and inclusive guide to the latest advancements in the field.

The 2020 Pharmacopoeia is designed to keep pace with the rapid changes in the pharmaceutical industry with a particular focus on innovation and evolution. Whether it is new production processes, the introduction of new drug categories or emerging drug delivery mechanisms, the Pharmacopoeia provides quality measures and guidance to ensure that such developments meet the highest standards of safety and efficacy.

Overall, the English version of the 2020 Pharmacopoeia represents a valuable resource for the pharmaceutical industry and individuals alike. The new release ensures that the latest standards are widely available and accessible across borders, making it easier to ensure the quality and safety of drugs sold and distributed in China from a global perspective. The Pharmacopoeia is an essential tool for ensuring the wellbeing of individuals and society as a whole and remains an important reference document in the ongoing efforts to improve global public health.

Further information

Here is the official Chinese Pharmacopoeia Commission website for access to the English version, however, it is nearly RMB8,000 per user for 5 years.

Reach out to Cisema if you have interest in any particular topics of the 2020 CP or discover our services for manufacturers of pharmaceuticals, packaging and ingredients.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

China General Cosmetics Urgent Deadline! Annual Reports Due 31 March
China Regulatory Round-up for Health Food from November 2020 to January 2021
China medical device supervision inspection results
China medical device supervision inspection results

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Registration of Pharmaceuticals in Hong Kong
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • china power switchgear control gear assemblies standard update

    China power switchgear and control gear assemblies standard GB/T 7251 update

    China power switchgear and control gear assembl...
  • China medical device supervision inspection results

    China medical device supervision inspection results

    China medical device supervision inspection res...
  • China toothpaste filing requirements

    China Toothpaste Filing Requirements

    China Toothpaste Filing Requirements were issue...
  • Building Successful China Medtech Market Entry Strategies

    Webinar | Building Successful China Medtech Market Entry Strategies – From the Market Access Perspective

    Building successful China Medtech market entry ...
  • China cosmetic regulatory violation

    China cosmetic regulatory violation cases reported by the NMPA

    China cosmetics regulatory violation cases were...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2003-2023 Cisema. All rights reserved.

TOP